Introduction
Materials and methods
Study population
Data linkage
Follow-up period
Outcome variables
CVD events | Nonfatal CVD events | Fatal CVD events | ||
---|---|---|---|---|
ICD-9 | ICD-10 | ICD-9 | ICD-10 | |
Ischaemic heart disease | 410–414 | I20–I25 | 410–414 | I20–I25 |
Cerebrovascular disease | 430–438 | I60–I69 | 430–438 | I60–I69 |
Heart failure | 428 | I50 | 428 | I50 |
Cardiac arrest/arrhythmias | 427 | I46–I49 | 427 | I46–I49 |
Cardiomyopathy | 425 | I42, I43 | 425 | I42, I43 |
Other diseases of circulatory system | - | - | 390-405, 415-417, 420-424, 426, 429, 440-459 | I00–I15, I26–I28, I30–I41, I44, I45, I51, I52, I70–I99 |
Statistical methods
Sensitivity analysis
Results
Patient characteristics
All-cause mortality cohort | CVD incidence cohort | |
---|---|---|
Characteristics | N (%) | N (%) |
N included | 477 | 381 |
Sex | ||
Male | 264 (55.3) | 218 (57.2) |
Age at start of RRT (years) | ||
0–<2 | 30 (6.3) | 29 (7.6) |
2–<6 | 50 (10.5) | 47 (12.3) |
6–<12 | 113 (23.7) | 90 (23.6) |
12–<18 | 284 (59.5) | 215 (56.4) |
PRD | ||
CAKUT | 229 (48.0) | 180 (48.6) |
GN | 80 (16.8) | 59 (15.5) |
Other | 168 (35.2) | 137 (36.0) |
Initial RRT modality | ||
HD | 220 (46.1) | 155 (40.7) |
PD | 207 (43.4) | 180 (47.2) |
Tx | 50 (10.5) | 46 (12.1) |
RRT modality during follow-up | ||
D + Tx+ | 371 (77.8) | 289 (75.9) |
Pre-Tx | 50 (10.5) | 46 (12.1) |
HD + Tx- | 30 (6.3) | 24 (6.3) |
PD + Tx- | 26 (5.5) | 22 (5.8) |
Survival after the start of renal replacement therapy
Cardiovascular disease incidence after the start of renal replacement therapy
Associations between determinants and all-cause mortality and cardiovascular disease incidence
Variable | All-cause mortality | CVD incidence | ||
---|---|---|---|---|
Crude HR (95% CI) | Adjusted HR (95% CI) | Crude HR (95% CI) | Adjusted HR (95% CI) | |
Age at start of RRTa | ||||
0–<2 | 2.41 (1.27–4.57) | 2.87 (1.42–5.82) | 0.73 (0.27–2.02) | 0.89 (0.31–2.59) |
2–<6 | 0.93 (0.60–1.44) | 1.39 (0.67–2.67) | 0.54 (0.23–1.25) | 0.77 (0.32–1.91) |
6–<12 | 0.97 (0.50–1.89) | 1.04 (0.66–1.64) | 0.67 (0.38–1.17) | 0.79 (0.44–1.41) |
12–18 | 1.00 | 1.00 | 1.00 | 1.00 |
Sexb | ||||
Males | 1.27 (0.89–1.82) | 1.31 (0.92–1.88) | 1.51 (0.96–2.38) | 1.76 (1.11–2.79) |
Females | 1.00 | 1.00 | 1.00 | 1.00 |
PRDc | ||||
GN | 0.99 (0.61–1.65) | 1.01 (0.61–1.69) | 1.17 (0.63–2.18) | 1.12 (0.59–2.19) |
Other | 1.45 (0.98–2.13) | 1.50 (1.01–2.22) | 1.46 (0.90–2.37) | 1.67 (1.01–2.75) |
CAKUT | 1.00 | 1.00 | 1.00 | 1.00 |
Initial RRT modalityd | ||||
HD | 2.97 (1.08–8.07) | 2.57 (0.92–7.18) | 2.04 (0.86–4.78) | 1.73 (0.73–4.11) |
PD | 2.41 (0.87–6.70) | 2.06 (0.73–5.85) | 1.17 (0.49–2.82) | 1.38 (0.56–3.41) |
Pre-Tx | 1.00 | 1.00 | 1.00 | 1.00 |
RRT modality during follow-upe | ||||
HD + Tx- | 14.4 (8.01–25.77) | 20.03 (10.77–37.25) | 5.51 (2.14–14.16) | 6.20 (2.29–16.80) |
PD + Tx- | 17.3 (9.71–30.76) | 20.69 (10.73–39.89) | 5.50 (2.41–12.55) | 5.81 (2.50–13.50) |
Pre-Tx | 0.55 (0.20–1.51) | 0.68 (0.25–1.86) | 0.74 (0.32–1.71) | 0.69 (0.30–1.61) |
D + Tx+ | 1.00 | 1.00 | 1.00 | 1.00 |